I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Angiotensin-converting enzyme (*ACE*) gene (MIM + 1061080) is located on chromosome 17. It produces an enzyme called *ACE* which plays an important role in renin angiotensin aldosterone system cascade by converting angiotensin I to angiotensin II. Previous studies suggested that *ACE* polymorphisms may be involved in the etiology of gestational diabetes mellitus (GDM) or Type 2 diabetes mellitus (noninsulin dependent diabetes mellitus \[NIDDM (MIM \#125853)\]). Studies have shown that RAS may play an important role in developing nephropathy in Type 2 diabetes mellitus, but the role of *ACE* polymorphisms in relation to Type 2 diabetes mellitus poorly understood.\[[@ref1]\] Several studies showed that an Alu insertion/deletion (*ACE I/D*) polymorphism located in intron 16 of *ACE* gene is associated with the high concentration of *ACE* levels in plasma.\[[@ref1]\] The role of other *ACE* polymorphisms in relation to patients with GDM or Type 2 diabetes mellitus has not been studied in Indian population till date. GDM women are at an increased risk of developing Type 2 diabetes mellitus later in their lives.\[[@ref2]\] Women with the family history of diabetes are at a risk of developing GDM.\[[@ref3][@ref4]\] The patho-physiology of GDM is similar to that of Type 2 diabetes mellitus and is characterized by peripheral insulin resistance accompanied by an insulin secretary defect.\[[@ref5][@ref6][@ref7]\]

The results of previous studies described the haplotype analysis of *ACE* gene polymorphisms in different populations, but with hypertension.\[[@ref8]\] Studies reported that a linkage disequilibrium (LD) block difference of haplotypes varies in different populations.\[[@ref8]\] This suggests that different LD of the polymorphisms located in *ACE* polymorphisms may be observed in different populations.\[[@ref8]\] Keeping these in view, the objective of this study was to analyze the role of these polymorphisms or given haplotypes with GDM and Type 2 diabetes mellitus patients in Indian population. Accordingly, we selected the following four polymorphisms *A-240T (ACE 4), ACE C1237T (ACE 6), A2350G (ACE 8)*, and *ACE I/D* in our study.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

These are detailed in the following sub-sections.

Study settings {#sec2-1}
--------------

A sample size of 10,000 women reporting to the OPDs of Obstetrics and Gynecology Department, All India Institute of Medical Sciences (AIIMS), New Delhi, India, during the period of May 2010 to June 2013, was screened for meeting the selection criteria. Out of this population, mainly the residents of North India, 344 subjects (120 controls, 105 GDM patients \[Group 1\], and 119 Type 2 diabetes mellitus \[Group 2\]) were enrolled in this study. Each subject\'s consent and the details of her medical and family history were documented through a set of questionnaires. The ethics committee of AIIMS approved the protocol of this study as well as patients\' medical/family history questionnaire. A detailed pedigree chart for each subject with family history was drawn and recorded.

Study subjects {#sec2-2}
--------------

Active groups were framed following on the characteristics of the diseased conditions namely, GDM (Group 1) and Type 2 diabetes mellitus (Group 2); and healthy women were enrolled to control group. The female subjects who suffered from hypertension, diabetes complications, cardiac diseases, metabolic syndromes (such as, obesity), cancers, HIV, gynecological-, endocrinological-, and neurological-disorders, any other type of diabetes or impaired glucose intolerance were excluded from the study. Each individual group is described in the following sub-sections.

Selection of active subjects {#sec2-3}
----------------------------

### Gestational diabetes mellitus (Group 1) {#sec3-1}

All pregnant women were screened with Carpenter and Coustan Oral Glucose Tolerance Test (OGTT) (threshold reading for 100 g glucose OGTT were fasting/1 h/2 h/3 h = 95/180/155/140 mg/dl) in 2^nd^ trimester of their gestation, but cases with the strong family history of Type 2 diabetes mellitus were screened in 1^st^ trimester for GDM. Patients who had \<2 OGTT values were excluded. The age of the patients in this group ranged between 18 and 42 years.\[[@ref9]\]

### Type 2 diabetes mellitus (Group 2) {#sec3-2}

This group consisted of 119 female subjects suffering from Type 2 diabetes mellitus with glucose levels for fasting/2 h ≥ 150/200 mg/dl or those with more than 2 high values of OGTT, for duration of more than a year and age \> 43 years (which is the average age of menopause in Indian women).\[[@ref10]\]

### Controls {#sec3-3}

Control group subjects were comprised of 120 healthy pregnant women with no reported clinical history of GDM or Type 2 diabetes mellitus. Blood samples from controls (of comparable age to that of GDM patients) were collected after screening with glucose test who had fasting/postprandial (PP) values (after 2 h) \<100/140 mg/dl. Patients with impaired glucose intolerance, GDM or Type 1/2 diabetes mellitus were excluded from this group.

Sample collection and DNA extraction {#sec2-4}
------------------------------------

Blood samples were collected after 8 h or overnight fasting form all the subjects included (controls, GDM and Type 2 diabetes mellitus) in this study. Genomic DNA was extracted from leukocytes of whole blood using the salting out method.\[[@ref11]\] The yield of extracted DNA was measured at 260/280-nm using a nano-drop (ND1000, Thermo, Delaware, USA) and purity was calculated by taking ratio of readings at 260/280 nm (acceptable ratios ranged between 1.6 and 2.0). The genomic DNA samples were stored at --20°C until further analysis.

Genetic analysis {#sec2-5}
----------------

The *ACE* gene single nucleotide polymorphisms that is, *A-240T* (rs4291), *ACE C1237T* (rs4309), *A2350G* (rs4343), and *ACE I/D* (rs4340) were amplified using QB-96 Server Gradient Thermocycler (Quanta Biotech, England), with the help of the previously published primers and methodology.\[[@ref12]\] Each PCR product of *ACE I/D* gene polymorphism, which were reported to be DD genotype, was subjected to a second PCR amplification with insertion-specific primers (FP5\'- TGGGACCACAGCGCCCGCCACTAC-3\'; RP: 5\' TCGCCAGCCCTCCCATGCCCATAA-3\') in order to avoid DD mistyping.\[[@ref13]\] The sequences of randomly selected samples (6 of each polymorphism) were analyzed through the software ABI3730XI (Applied Biosystem, Texas, USA). The result of this sequence analysis for the above-mentioned polymorphisms (*ACE 4, ACE 6, ACE 8*, and *ACE I/D*) confirmed our genotyping results (all PCR and RFLP chemicals were bought from Fermentas, USA).

Statistical analysis {#sec2-6}
--------------------

Demographics and clinical variables between active groups and controls were analyzed with Stata 11.0 (College Station, Texas, USA) for windows. Numerical variables not normally distributed were presented as mean ± standard deviation and median (range) and were compared using ANOVA/Krushkal-Wallis test, followed by Bonferroni correction. Logistic regression analyses were used to test for the association of polymorphisms or haplotypes with GDM and Type 2 diabetes mellitus. Statistical significance was set at *P* \< 0.05. SHEsis software (<http://analysis.bio-x.cn>; Shi and He, 2005) was used to construct two/three and four locus haplotypes.\[[@ref14]\]

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Characteristics of study subjects {#sec2-7}
---------------------------------

The statistical analyses of demographic data and clinical profile of 2 active groups and controls showed that there was the insignificant difference in mean age of Group 1 cases (*P* = 0.16) in comparison with that of controls. However, there was a significant difference in the mean age of Group 2 cases when compared to controls (*P* \< 0.001) and Group 1 cases (*P* \< 0.001). Patients with multigravida were approximately 75% in both controls and Group 1. Group 2 had the maximum number of children (50%) in comparison with that of controls (10%) and Group 1 (5%). Group 1 (GDM) had the strongest family history of NIDDM with mother (*P* = 0.02), father (*P* = 0.01) or both (*P* = 0.001); and highest percentage of GDM occurrence (12.3%) and cesareans (13.33%) in their previous pregnancies. The difference in mean fasting and PP glucose levels in all the groups were statistically significant (*P* \< 0.001).

Allele and genotype frequencies {#sec2-8}
-------------------------------

The genotype frequencies of *ACE 4, ACE 6, ACE 8*, and *ACE I/D* are shown in [Table 1](#T1){ref-type="table"}. [Table 1](#T1){ref-type="table"} exhibits that genotype TT of *ACE* 6 (*P* = 0.004) and genotype GG of *ACE 8* (*P* \< 0.001) gene polymorphisms were significantly associated with GDM. The chances of developing Type 2 diabetes mellitus in postpregnancy of GDM patients with genotype DD of *ACE I/D* were found to be increased by 2.14 folds (95% confidence interval: 1.14-4.13). [Table 2](#T2){ref-type="table"} depicts the allele frequencies of *ACE 4, ACE 6, ACE 8*, and *ACE I/D* and each one differed significantly between active groups and controls. According to recessive model,\[[@ref8]\] allele T of *ACE 6* (*P* = 0.008) and according to dominant model,\[[@ref8]\] allele G of *ACE 8* (*P* \< 0.001) were observed to be associated with GDM \[[Table 1](#T1){ref-type="table"}\]. Allele G of *ACE 8* was also associated with Group 2 cases (*P* \< 0.001).

###### 

Genotype and allele frequencies of *ACE 4, ACE 6, ACE 8* and *ACE I/D* polymorphisms

![](IJABMR-6-31-g001)

###### 

Observed 3 locus haplotypes of *ACE 4, ACE 6, ACE 8* and *ACE I/D* polymorphisms and haplotype frequency analysis in groups and controls

![](IJABMR-6-31-g002)

Haplotype frequencies {#sec2-9}
---------------------

The LD analysis was made of four *ACE* polymorphisms in individuals and combined groups [Figure 1a](#F1){ref-type="fig"}--[e](#F1){ref-type="fig"}\]. Haplotype analysis of *ACE 4, ACE 6, ACE 8*, and *ACE I/D* gene polymorphisms were carried out by combining them in the loci of two, three, and four respectively. A total of 24 haplotype combinations were formed both in two-locus and three locus haplotypes of which sixteen haplotypes were significant \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\]. In four loci haplotype analyses only eight out of sixteen haplotype combinations were found to be significant \[[Table 4](#T4){ref-type="table"}\]. All polymorphisms (*ACE 4, ACE 6, ACE 8*, and *ACE I/D*) with high LD (D\' values = 0.9 and *r*^2^ values = 0.8) were reanalyzed.

![Graphical overview of pair-wise linkage disequilibrium analysis of the investigated polymorphisms. (a) Controls; (b) Group 1; (c) Group 2; (d) Combined data of Group 1 and controls; (e) Combined data of Group 2 and controls](IJABMR-6-31-g003){#F1}

###### 

Observed 2 locus haplotypes of *ACE 4, ACE 6, ACE 8* and *ACE I/D* polymorphisms and haplotype frequency analysis in groups and controls

![](IJABMR-6-31-g004)

###### 

Observed 4 locus haplotypes of *ACE 4, ACE 6, ACE 8* and *ACE I/D* polymorphisms and haplotype frequency analysis in groups and controls

![](IJABMR-6-31-g005)

Haplotype analyses of two-locus haplotypes {#sec2-10}
------------------------------------------

From [Table 3](#T3){ref-type="table"}, it appears that two loci haplotypes H1, H5, H8, and H14 were the protected ones in both active groups but haplotypes H2, H9, H11, and H15 were significantly associated as risk ones in these groups. In an individual group, the situation is different, and it is stated as follows. Haplotype H6 was found to be associated (risk) and haplotypes H7 and H12 were observed to be protective in Group 1 (GDM). In Group 2 haplotypes, H3, H10, and H13 were protective and H4 and H16 were risk haplotypes.

Three locus haplotype analysis {#sec2-11}
------------------------------

[Table 2](#T2){ref-type="table"} shows that haplotype L2 was protective in Group 1 whereas haplotypes L1, L4, L5, L9, and L13 were strongly associated with Group 1. In Group 2, haplotypes L3 and L10 were protective but L11 and L16 was only risk haplotypes. Haplotypes L6, L8, L12, and L15 were protected in both groups. Strong association of haplotypes L7 and L14 with both groups were observed.

Haplotype analysis of four locus haplotypes {#sec2-12}
-------------------------------------------

[Table 4](#T4){ref-type="table"} shows four loci haplotypes depicting T1 and T4 to be protective in both groups. Haplotypes T2 and T5 were strongly associated with both active groups. In Group 1, haplotype T7 was statistically significant. In Group 2, haplotypes T3 and T8 may be a disease causing haplotypes, whereas T6 may play a protective role.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

GDM is defined as any glucose intolerance detected during pregnancy.\[[@ref15]\] Epidemiological studies revealed that GDM may be associated with increased feto-maternal morbidity and long-term complications in mothers and off-spring.\[[@ref15]\] The etiologic role of genes implicated in RAS has been widely studied. Several clinical studies have reported a possible association between *ACE* polymorphisms and pathological phenotypes.\[[@ref14][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] The present study shows the relation between four *ACE* polymorphisms in a group of North Indian pregnant women with or without GDM. Two out of four polymorphisms (*ACE 6* and *ACE 8*) were found to be associated with GDM patients. These associations were independent of other diabetes-associated risk factors. *ACE 4* and *ACE I/D* were associated neither with GDM nor with Type 2 diabetes mellitus patients. Of the studied polymorphisms, only *ACE I/D* were previously studied in patients with GDM and Type 2 diabetes mellitus in various populations.\[[@ref25][@ref26]\] The association of *ACE I/D* with GDM were contradictory, as in Asian Indian population DD genotype was strongly associated with GDM, but in Czechoslovakian population it was reported to be absent.\[[@ref25][@ref26]\]

Linkage disequilibrium {#sec2-13}
----------------------

According to LD analysis, 4 polymorphisms (*ACE 4, ACE 6, ACE 8*, and *ACE I/D*) were in LD with statistical significance \[[Figure 1a](#F1){ref-type="fig"}--[e](#F1){ref-type="fig"}\] and constructed various haplotypes: One of them associated with highest risk (T7: TTAI) and the other was significantly protective (T5: TAAI) for GDM. To the best of our knowledge, haplotype studies on *ACE* polymorphism, besides hypertension or Alzheimer disease, and diabetes complications are not reported till date. Zhu *et al*. studied 10 polymorphisms in hypertensive patients from African-American and European-American populations.\[[@ref27]\] The authors reported a haplotype with three polymorphisms associated with hypertension and the haplotype association was different in African-American and European-American subjects.\[[@ref27]\] In the African-Americans, the haplotype associated included rs4343, rs4353, and rs4363 polymorphisms (AAA haplotype), and in European-Americans the haplotype included the rs4335, rs4343, and rs4344 polymorphisms (GGG haplotype). The risk haplotype in the Mexican Mestizo population includes rs4335 G and rs4344 G alleles. On the other hand, rs4353 A allele was detected in African-American as well as in European-American population.

The most studied *ACE* gene polymorphism, in this case, is I/D. In a study by Zhu *et al*.,\[[@ref12]\] two polymorphisms (*ACE 8* and *ACE 4*) accounted for the variation of *ACE* concentrations. *ACE 8* had the most significant effect, and accounted for 19% of the total variation in *ACE* levels, while *ACE 4* located in the 5\' promoter region of the gene accounted for 6% of the variation. After adjustment for the effect of *ACE 4, I/D* polymorphism was found to be no longer associated with *ACE* levels, indicating that it is in LD with *ACE 8* and unlikely to be a functional polymorphism.\[[@ref12]\] The association of other *ACE* polymorphisms with *ACE* levels was reported to be contradictory with positive and negative associations.\[[@ref28][@ref29][@ref30]\] The association *ACE 4* polymorphism was absent in hypertensive Mexican Mestizo population.\[[@ref8]\] In this study too, the association *ACE 4* with GDM and Type 2 diabetes mellitus was observed to be absent.

Limitations of the study {#sec2-14}
------------------------

The limitations of our study were inherited in the fact that *ACE* levels were not measured, and the study sample size was restricted to *n* = 344 comprising of 3 groups. The *ACE* levels could not be estimated in GDM patients because blood samples collecting varied at months of pregnancy for all patients (as some patients developed GDM in different trimesters of pregnancy).\[[@ref25]\] Moreover, the T2DM patients were already in *ACE*-inhibitor drugs, which could have misled the estimated level. This pilot study has indicated the plausibly valuable associations of the polymorphism with the diseased conditions of a specific population. Hence, this study may be extended to other ethnic groups in establishing different regulatory regions in *ACE* gene along with *ACE* levels.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

In summary, our results suggested that the *ACE 4, ACE 6 ACE 8* and *ACE I/D ACE* gene polymorphisms might play an important role in the development of GDM and NIDDM in North Indian women population. In our study, it was possible to identify risk haplotypes and protective haplotypes for GDM and NIDDM. Individuals with the risk haplotype showed increased Glucose levels as compared to individuals with the protective haplotype.
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